Radicava/Edaravone Findings in Biomarkers From Amyotrophic Lateral Sclerosis (REFINE-ALS): Protocol and Study Design

Conclusions
Findings may help to further the understanding of the pharmacodynamic effect of edaravone, including changes in biomarkers, in response to treatment.

Source: Neurology Clinical Practice - August 9, 2021 Category: Neurology Authors: Berry, J., Brooks, B., Genge, A., Heiman-Patterson, T., Appel, S., Benatar, M., Bowser, R., Cudkowicz, M., Gooch, C., Shefner, J., Westra, J., Agnese, W., Merrill, C., Nelson, S., Apple, S. Tags: All Clinical Neurology, Amyotrophic lateral sclerosis, All Clinical trials, Clinical trials Methodology/study design Research Source Type: research